The objective of this study was to examine the changes in level of respiratory support following transfusion in neonates who require intermediate or intensive care. STUDY DESIGN: Data on respiratory support were collected retrospectively from the medical record before, during and after transfusion. Neonatal post transfusion lung injury (NPTLI) was defined as an increase in the highest mean airway pressure (MAP) of X2 cm H 2 O or FiO 2 40.15 in the 6-h after transfusion that persisted from 6 to 18 h post transfusion. RESULT: A total of 373 (330 packed red blood cell) transfusions were given to 108 infants. NPTLI occurred following 31 (8.3%) transfusions in 23 patients. During the first 6 h after transfusion, FiO 2 or MAP was increased in 47 transfusions (12.6%) and the changes persisted in 31 transfusions (7.8%). Infants who developed NPTLI were less mature (27.1 ± 0.7 vs 31.0 ± 0.5 weeks; P ¼ 0.005) and of lower birth weight (1001±110 vs1692±104 g; P ¼ 0.001). Infants who developed NPTLI were more likely to develop necrotizing enterocolitis (6/24 vs 4/85; P ¼ 0.002) and die within 24 h of transfusion (5/22 vs 3/85; P ¼ 0.003). CONCLUSION: In neonates receiving intensive or intermediate care, blood transfusion was associated with need for increased respiratory support in a significant number of cases. Development of NPTLI was associated with poorer outcomes.
INTRODUCTION
Transfusion-related acute lung injury (TRALI) has been recognized as a clinical entity since the early 1950s. 1, 2 Initially reported in adult patients, TRALI is now recognized as a rare but important complication of transfusion in all age groups including children. [3] [4] [5] [6] Although most cases of TRALI resolve with supportive care, it is currently one of the leading causes of mortality following transfusion of blood products. [7] [8] [9] Despite its importance, TRALI is believed to be largely under recognized and underreported. 10 Traditionally, the diagnosis of TRALI is made only in patients without pre-existing lung disease. These patients develop acute lung injury (ALI), primarily non-cardiogenic pulmonary edema, within 6 h of receipt of a blood product. 11, 12 It has become apparent, however, that critically ill patients with pre-existing lung injury may demonstrate worsening of pulmonary function following transfusion. 13, 14 The diagnostic criteria for TRALI were namely, respiratory distress, cyanosis, hypotension and fever; all may be present to a greater or lesser degree in a critically ill patient making the diagnosis of TRALI problematic in this population.
TRALI results from damage to the pulmonary endothelium and subsequent increased capillary permeability leading to pulmonary edema. This may occur as a result of preformed leukocyte antibodies in donor's plasma binding to neutrophils of the recipient with activation, sequestration and degranulation within pulmonary capillaries. [15] [16] [17] [18] [19] [20] [21] [22] Alternatively, TRALI may arise from a multi-hit mechanism in which the underlying clinical condition of the patient primes the lung and makes it more vulnerable to injury (second hit) by infusion of a blood product containing biologically active mediators that accumulate during storage. [23] [24] [25] The common pathway of either mechanism is granulocyte activation, degranulation and release of inflammatory mediators that damage the pulmonary vascular endothelium.
There is little information on whether TRALI occurs in neonates. 26, 27 This is despite the very high prevalence and numbers of blood transfusions in the neonate (particularly preterm infants) requiring intensive care. The neonate receiving intensive care may be particularly vulnerable to a 'two hit' mechanism of lung injury following transfusion. Infection, birth asphyxia, cardiopulmonary disease, ventilator-induced lung injury, all common in the preterm infant, could prime the lung for further injury. The lack of reports of TRALI in this population are likley to lack of awareness, absence of consensus on the definition or difficulty in diagnosis due to other confounding factors. It is probable that the pulmonary injury induced by blood product transfusion occurs in the neonate but is masked by the existence of the concurrent diseases.
We sought to understand the effects of transfusion may have on pulmonary function in newborn infants who may or may not have pre-existing lung injury or other cofounders. To accomplish this, we undertook a retrospective analysis of changes in respiratory support following transfusion in neonates.
METHODS
We retrospectively examined the changes in level of respiratory support following transfusion in neonates receiving level II or level III neonatal care. The study was approved by the Health Research Ethics Board at the University of Manitoba.
Newborn infants (both inborn and outborn) admitted to either the neonatal intensive or intermediate care units at Health Sciences Centre, Winnipeg, Manitoba, Canada from June 2005 to May 2007 were eligible for inclusion. Infants were included in the study if they met the following inclusion criteria; received any form of blood product, neonatal intensive care or intermediate care inpatient at the time of transfusion, and cardiopulmonary status did not change significantly in the 6-h before transfusion (no change in mode of ventilation, less than 1 cm H 2 O variation in mean airway pressure (MAP) and less than 0.15 variation in FiO 2 ). Infants were excluded from review if they had a severe lung problem, for example, hypoplasia, diaphragmatic hernia, persistent pulmonary hypertension requiring nitric oxide therapy, unstable congenital heart disease and multiple congenital anomalies were transfused in pediatric wards or if patient record was unavailable.
Infants were transfused at the discretion of the team caring for the infants. We did not have an institutional guideline for transfusion of infants at the time. All packed red blood cells (PRBC) were cytomegalovirus negative, leucoreduced and irradiated before transfusion. Citrate phosphate dextrose was used as preservative for PRBCs. Multiparous women were not excluded as donors for PRBC during this time. Single donor sources were not used. Generally 20 ml kg À 1 of PRBC are given over 3 h in our unit. Feeds were not stopped during transfusions.
Data were collected from the period 6 h before, during, and 0 to 6 and 6 to 18 h after each transfusion. Each transfusion was considered as a separate event. In the case of multiple transfusion, there had to be more than 6 h separating the transfusions to consider them independently. This duration was selected to allow sufficient time for lung injury to develop, and it conforms to the time period for developing TRALI in the adult.
Data were collected for each transfusion from the medical record. In an attempt to minimize bias in selecting which vital sign to record, we chose the maximal degree of respiratory support that occurred in each period. Thus, for each time period, we recorded the maximum MAP recorded, the maximum FiO 2 used and the mode of support. Other physiological parameters (heart rate, respiratory rate, systolic blood pressure) and transfusion details (type, volume and age of blood product transfused, hematological values pre and post transfusion) were also recorded. Patient demographics and outcomes (mortality, chronic lung disease, length of hospital stay) were collected for patients transfused.
We considered that some degree of TRALI occurred if (compared to the pre transfusion period) there was an increase in the MAP of X2 cm H 2 O or FiO 2 40.15 in the 6-h after transfusion that persisted from 6 to 18 h post transfusion. To avoid confusion with definite TRALI, we will refer to this as neonatal post transfusion lung injury (NPTLI).
Data analysis
Changes in MAP and FiO 2 following transfusion were compared by using ANOVA for repeated measures. When sphericity could not be assumed, the most conservative estimate of significance was used (GreenhouseGeisser). 28 Comparison between transfusions with NPTLI and those without were made by w 2 for categorical comparisons. Unpaired t-tests were used to compare group means. Bonferonni correction of values was not made. Non-normally distributed data and ordinal data were compared using Mann-Whitney U Test.
For multivariable analysis, non-conditional multiple logistic regressions were used. Variables in the analysis included birth weight, gestation, receipt of surfactant, necrotizing enterocolitis (NEC) and NPTLI. Statistical analysis was performed using IBM SPSS version 19.0 (Armonk, NY). A probability value of less than 0.05 was considered statistically significant. The data are presented as mean±standard error of the mean or median and intraquartile range where appropriate.
RESULTS
One hundred and eight newborn infants met the inclusion criteria within the study period. Infants who received blood transfusion were mainly premature infants (68 very low birth weight infants) who had received surfactant therapy and mechanical ventilation for respiratory distress syndrome at some point during their hospitalization. These 108 infants received 373 transfusions (median 2 IQR 1 to 6; range 1 to 20 transfusions) of which the majority was PRBC. The majority of transfusions were given to very low birth weight infants (85%). Characteristics of the transfusions are shown in Table 1 .
During the first 6 h after transfusion, FiO 2 requirement or MAP was significantly increased on 47 (12.6%) occasions. In 25 cases, it was due to an increase in FiO 2 , 21 cases due to an increase in MAP and both in 1. These changes persisted from 6 to 18 h after transfusion on 31 (7.8%) occasions in 23 patients and met our proposed definition of NPTLI in the neonate. Infants who developed NPTLI were of lower gestational age and of lower birth weight (Table 2 ). There were no differences in gender and postnatal age of infants receiving blood transfusion who developed NPTLI when compared with those who did not. Neither the number of previous transfusions, age of the blood product, type of blood product nor volume transfused was associated with NPTLI. The presence of patent ductus arteriosus before transfusion and diuretic use during transfusion were not different between transfusions with or without NPTLI. In the patients with NPTLI, there were no significant changes in WBC and differential counts after transfusion compared with the pretransfusion period (data not shown).
The degree of respiratory support was similar in the 6-h before transfusion in NPTLI episodes and transfusions where NPTLI did not develop (Table 3) The use of supplemental oxygen alone was greater in the pre-transfusion period in NPTLI episodes but the need for mechanical ventilation or continuous positive airway pressure was similar between the groups. Inspired oxygen concentration tended to be higher but MAP was similar in the pre-transfusion period in NPTLI episodes. Both MAP and FiO 2 increased during the post-transfusion period in NPTLI episodes, whereas no change in either parameter occurred in transfusions where NPTLI did not develop (Figures 1 and 2 ).
Outcomes were worse in infants who developed NPTLI. Infants who developed NPTLI using this definition were less likely to survive to discharge (14/23 vs 80/85; Po0.001), more likely to receive corticosteroids for evolving chronic lung disease (6/23 vs 6/85; P ¼ 0.007) and were more likely to die within 24 h of transfusion (5/23 vs 3/85; P ¼ 0.003). NEC was more common in infants with NPTLI (6/23 vs 4/85; P ¼ 0.002). Four infants developed NEC not temporally associated with transfusion, two of which developed NPTLI. Six infants developed NEC within 48 h of transfusion of which three developed NEC and NPTLI concomitantly, two did not develop NPTLI and a single patient with NEC developed worsening pulmonary failure after a transfusion.
Long-term pulmonary morbidity (bronchopulmonary dysplasia) was not different (4/23 vs 8/85; P ¼ 0.374) between infants with NPTLI and those without. After controlling for NEC, gestation, birth weight and surfactant therapy, NPTLI, as defined in this study, remained a significant negative predictor of survival to discharge ( Table 4 ). Development of NEC was a significant predictor of death within 24 h of transfusion.
DISCUSSION
We found that in infants receiving intensive or step-down care, transfusion was associated with a persistent worsening of lung Post transfusion lung injury in neonates N Rashid et al function and increased need for respiratory support after about 8% of transfusions. This apparent worsening in lung function, which we have named NPTLI, occurs at a far greater rate than TRALI in which there is no pre-existing lung injury. 29, 30 This relatively high incidence of lung injury is similar to that described in critically ill adults. In critically ill adults, ALI occurs in as many as 25% of patients after blood transfusion and is associated with a mortality of up to 40%. 31 We also found that NPTLI was associated with a similar degree of mortality. Additionally, the development of ALI in critical illness may be delayed from 6 to 72 h after the transfusion. 13, 32 There was evidence of delayed development of ALI in our study as greater numbers of infants had MAP42 cm H 2 O at 6 to 18 h after transfusion.
The number of transfusions before developing NPTLI was not different between NPTLI episodes and non-NPTLI transfusions. This is different than reported for TRALI in other studies. 13, 30, 32 However, in those studies, the total number of transfusions received by patients who developed ALI was compared with those patients without ALI. When we make a similar comparison, we also find that the numbers of total transfusions was greater in the NPTLI infants. TRALI is more frequently diagnosed after transfusion of plasma-rich blood products such as platelets. 33 We did not see any cases of NPLI after platelet or fresh-frozen plasma transfusion. This was most likely due to the relatively small numbers of these types of transfusions in our study.
The birth weight and gestational age of infants who developed NTRLI was less than those who did not. Several factors could explain this finding. First, less mature infants are transfused more often and receive a greater number of transfusions than their more mature counterparts and thus are exposed more often. This was true in our study as the majority of transfusions were given to very low birth weight infants. Less mature infants are more likely to have underlying lung injury and may be more vulnerable to additional injury from the transfusion. However, in our study, the actual degree of respiratory support before the development of NTRLI was similar. Although lower birth weight and gestation may have predisposed the infants to NTRLI but in itself was not the reason for increased respiratory support after transfusion.
Deterioration in pulmonary function could have occurred due to underlying disease progression as many of the infants in this study were ventilated and at least moderately ill at the time of NTRLI. Although this is undoubtedly true for some of the patients classified as NTRLI, all infants had no significant changes in mode of ventilator support, inspired oxygen concentration or MAP in the 6-h preceding transfusion. In critically ill adults, transfusion was independently associated with the development of acute respiratory distress syndrome after controlling for disease severity. 13 Several authors stress the differentiation of TRALI from acute volume overload. 34 Acute fluid overload is less likely an explanation for the changes seen in pulmonary function as the volume transfused, presence of a patent ductus arteriosus and use of furosemide was similar between NPTLI and control transfusions.
The occurrence of NEC either concomitantly or following NPTLI is of note. Recent reports suggest an association between NEC and transfusion. 35, 36 Our study was initiated before these reports and was not designed to look for this association. Nevertheless, we found NEC occurring within 48 h of transfusion in six cases and half were associated with NPTLI. Only one prior study made mention of respiratory support before the onset of transfusionassociated NEC (TANEC) and none commented on changes in respiratory support. The combination of NEC with NPTLI appears to be particularly ominous with death occurring within 24 h. The lower gestational age and birth weight of infants with TANEC is similar to that seen for NPTLI and may suggest a common pathway to injury in both situations. This may reflect additional transfusion-induced endothelial injury to vascular beds with preexisting injury. The additional injury may manifest itself as either TANEC or NPTLI or both.
Although our study is limited by its retrospective design and small sample size, this is the largest series reporting acute pulmonary deterioration in newborn infants following blood product transfusion to date. The criteria used for diagnosis of TRALI in adults are too restrictive for the majority of our newborn infants who receive blood products. Refining the criteria for the definition of TRALI to make it more applicable to newborn infants is necessary.
Our study suggests that blood product transfusion can lead to an acute pulmonary deterioration in a small but clinically significant proportion of newborn infants, particularly in those receiving respiratory support. To more accurately define the incidence, clinical course, further identify predisposing factors, and determining etiology, it will be necessary to carry out prospective studies of newborns receiving blood product transfusions. 
